Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy
Publication Date: January 1, 2015
Last Updated: March 14, 2022
Recommendations
The AGA recommends antiviral prophylaxis over no prophylaxis for patients at high risk undergoing immunosuppressive drug therapy. (Moderate, Strong)
Comments: Treatment should be continued for at least 6 months after discontinuation of immunosuppressive therapy (at least 12 months for B cell– depleting agents).
612
Title
Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy
Authoring Organization
American Gastroenterological Association